Arteriovenous malformations (AVMs) are defects of the circulatory system that are generally believed to arise during embryonic or fetal development or soon after birth. Although AVMs can develop in many different sites, those located in the brain or spinal cord can have especially widespread effects on the body. Most people with neurological AVMs experience few, if any, significant symptoms. The malformations tend to be discovered only incidentally, usually either at autopsy or during treatment for an unrelated disorder. But for about 12 percent of the affected population (about 36,000 of the estimated 300,000 Americans with AVMs), these abnormalities cause symptoms that vary greatly in severity.
Medication can often alleviate general symptoms such as headache, back pain, and seizures caused by AVMs and other vascular
lesions. However, the definitive treatment for AVMs is either surgery or focused irradiation therapy. The decision to perform surgery on any individual with an AVM requires a careful consideration of possible benefits versus
risks.
The greatest potential danger posed by AVMs is hemorrhage. Researchers believe that each year between 2 and 4 percent of all
AVMs hemorrhage. Most episodes of bleeding remain undetected at the time they occur because they are not severe enough to
cause significant neurological damage. But massive, even fatal, bleeding episodes do occur. Whenever an AVM is detected, the
individual should be carefully and consistently monitored for any signs of instability that may indicate an increased risk
of hemorrhage.
Researchers are studying large populations of individuals with AVMs to formulate criteria that will allow doctors to predict
more accurately the risk of hemorrhage. Of particular importance is the role that high blood pressure within the lesion plays
in the onset of hemorrhage. Other scientists are examining the genetic basis of familial cavernous malformations and other
hereditary syndromes that cause neurological vascular lesions, including ataxia telangiectasia.
Other scientists are seeking to refine the techniques now available to treat AVMs. One study is closely examining the precise
effects that radiation exposure has on vascular tissue in order to improve the predictability and consistency of treatment
results. Several studies are devoted to developing new noninvasive neuroimaging technologies to increase the effectiveness
and safety of AVM surgery. Some scientists are pioneering the use of MRI to measure amounts of oxygen present in the brain
tissue of patients with vascular lesions in order to predict the brain’s response to surgical therapies. Others are developing
a new micro-imager that may be inserted into catheters to increase the accuracy of angiography. In addition, new types of
noninvasive imaging devices are being developed that detect functional brain activity through changes in tissue light emission
or reflectance.
National Organization for Rare Disorders (NORD) 55 Kenosia Avenue Danbury, CT 06810 orphan@rarediseases.org http://www.rarediseases.org Tel: 203-744-0100 Voice Mail 800-999-NORD (6673) Fax: 203-798-2291 |
International RadioSurgery Association 2960 Green Street P.O. Box 5186 Harrisburg, PA 17110 irsa@irsa.org http://www.irsa.org Tel: 717-260-9808 Fax: 717-260-9809 |
Prepared by:
Office of Communications and Public Liaison
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD 20892
NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.
All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.
Last updated February 4, 2013